| Completed | Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Dise Chronic Graft Versus Host Disease | Phase 1 / Phase 2 | 2018-11-19 |
| Completed | Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL) Mantle-Cell Lymphoma | Phase 3 | 2017-06-19 |
| Completed | Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants W Chronic Graft Versus Host Disease | Phase 3 | 2017-05-11 |
| Completed | Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma Follicular Lymphoma | Phase 3 | 2017-01-23 |
| Completed | Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lym Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | 2016-09-28 |
| Terminated | Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Mul Multiple Myeloma | Phase 1 / Phase 2 | 2016-03-01 |
| Completed | Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary T Metastatic Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Advanced Gastric Adenocarcinoma | Phase 1 / Phase 2 | 2015-12-01 |
| Completed | informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia (CLL) | — | 2015-09-01 |
| Completed | Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment Metastatic Pancreatic Adenocarcinoma | Phase 3 | 2015-05-01 |
| Completed | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphom Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | Phase 1 / Phase 2 | 2015-05-01 |
| Completed | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid T Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer | Phase 1 / Phase 2 | 2015-03-01 |
| Terminated | Study of Ibrutinib in Subjects With Acute Myeloid Leukemia Acute Myeloid Leukemia (AML) | Phase 2 | 2015-02-01 |
| Completed | A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obi Chronic Lymphocytic Leukemia, Small-Cell Lymphoma | Phase 3 | 2014-10-06 |
| Completed | Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease Graft Versus Host Disease | Phase 1 / Phase 2 | 2014-07-14 |
| Completed | Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia Waldenström's Macroglobulinemia | Phase 3 | 2014-07-07 |
| Completed | Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cel Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory | Phase 1 / Phase 2 | 2014-05-01 |
| Completed | Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse L Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | 2014-03-13 |
| Completed | Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocyti Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | 2013-12-03 |
| Completed | Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma Marginal Zone Lymphoma, B-cell Lymphoma | Phase 2 | 2013-12-01 |
| Completed | Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma Follicular Lymphoma, B-cell Lymphoma, Non-Hodgkin's Lymphoma | Phase 2 | 2013-12-01 |
| Completed | Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Mul Multiple Myeloma | Phase 1 / Phase 2 | 2013-12-01 |
| Completed | Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | 2013-03-01 |
| Completed | A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia With 17p Deletion, Small Lymphocytic Lymphoma With 17p Deletion | Phase 2 | 2013-01-01 |
| Completed | A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lym Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | 2012-06-01 |
| Completed | Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Multiple Myeloma | Phase 2 | 2012-03-01 |
| Completed | Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymp Diffuse Large Cell B-lymphoma | Phase 2 | 2011-05-01 |
| Completed | Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL) Mantle Cell Lymphoma | Phase 2 | 2011-02-01 |
| Completed | Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bend B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | 2011-02-01 |
| Completed | Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocyctic Leukemia | Phase 1 / Phase 2 | 2010-12-01 |
| Completed | A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer Lymphoma, Non-Hodgkin's Lymphoma, Hodgkin Disease | Phase 1 | 2010-06-01 |
| Completed | Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Well-differentiated Lymphocytic Lymphoma | Phase 2 | 2010-06-01 |
| Completed | Safety of PCI-32765 in Chronic Lymphocytic Leukemia B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | 2010-05-01 |
| Completed | Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment Pancreatic Cancer, Ductal Adrenocarcinoma, Exocrine Pancreatic Cancer | Phase 2 | 2009-11-01 |
| Completed | Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma B-Cell Lymphoma, B-Cell Leukemia | Phase 1 | 2009-02-01 |
| Completed | Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma Lymphoma, Hodgkin Disease, Lymphoma, Non-Hodgkin | Phase 1 / Phase 2 | 2008-07-01 |
| Completed | Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients Neoplasms by Site, Lymphoma, Non-hodgkin, Hodgkin Disease | Phase 1 | 2007-11-01 |
| Terminated | Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Ce Non-Small Cell Lung Carcinoma | Phase 2 | 2006-06-01 |
| Terminated | Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used i Lung Cancer | Phase 2 | 2006-05-01 |
| Completed | Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Leukemia | Phase 1 / Phase 2 | 2005-11-01 |
| Completed | Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer Adenocarcinoma, Non-Small-Cell Lung Carcinoma, Lung Neoplasms | Phase 2 | 2005-09-01 |
| Completed | Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients Hematologic Neoplasms, Neoplasms | Phase 1 | 2005-08-01 |
| Completed | A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small C Non-Small-Cell Lung Carcinoma, Carcinoma, Bronchogenic | Phase 1 | 2004-11-01 |
| Terminated | Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphom Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | 2004-10-01 |
| Completed | Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain Metastases Metastatic Cancer | Phase 3 | 1998-08-01 |
| Terminated | Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost i Neoplasm Metastasis, Brain Neoplasms | Phase 2 | — |
| Completed | Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer Carcinoma, Renal Cell, Urogenital Neoplasms, Urologic Neoplasms | Phase 2 | — |
| Terminated | Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cance Head and Neck Cancer, Oropharynx Cancer, Larynx Cancer | Phase 1 | — |
| Completed | Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma Lymphoma, Non-Hodgkin's Lymphoma | Phase 2 | — |
| Completed | Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms | Phase 1 | — |
| Completed | Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART) Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Metastases, Neoplasm | Phase 3 | — |
| Completed | A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas Glioma, Glioblastoma, Astrocytoma | Phase 1 | — |
| Completed | Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms | Phase 1 | — |
| Completed | A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma Multiple Myeloma | Phase 2 | — |
| Terminated | A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL) Leukemia, Leukemia, Lymphocytic, Chronic | Phase 2 | — |